Improving cancer treatment with targeted radioactive drugs
MIRDcell Version 3
['FUNDING_R01'] · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · NIH-11006254
This study is looking at new ways to deliver radioactive treatments directly to cancer cells to make them work better while protecting healthy tissues, so patients can have improved options for managing their cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RUTGERS BIOMEDICAL AND HEALTH SCIENCES (nih funded) |
| Locations | 1 site (Newark, UNITED STATES) |
| Trial ID | NIH-11006254 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the effectiveness of radiopharmaceutical therapy (RPT) for cancer by developing better methods to deliver radioactive drugs directly to tumors and cancer cells. It aims to optimize treatment planning to maximize the therapeutic effects while minimizing harm to healthy tissues. By studying different types of radiation and their biological impacts, the research seeks to address challenges in treating microscopic disease that traditional methods may not effectively target. Patients may benefit from improved treatment strategies that could lead to better outcomes in managing their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that have metastasized or those with disseminated tumor cells that are difficult to treat with conventional therapies.
Not a fit: Patients with early-stage localized cancers that can be effectively treated with surgery or external beam radiation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer cancer treatments using targeted radioactive therapies.
How similar studies have performed: Previous research has shown promise in using radiopharmaceuticals for cancer treatment, indicating that this approach has potential for significant advancements in therapy.
Where this research is happening
Newark, UNITED STATES
- RUTGERS BIOMEDICAL AND HEALTH SCIENCES — Newark, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HOWELL, ROGER W. — RUTGERS BIOMEDICAL AND HEALTH SCIENCES
- Study coordinator: HOWELL, ROGER W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy